Interventional Glaucoma

Until new innovations began transforming the field a decade ago, ophthalmologists had a limited toolbox. This option allows ophthalmologists to provide positive outcomes for their patients.

BVS Sight Inc. was created through a partnership between Boomerang Ventures and Purdue Research Foundation.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

Janey Wiggs, MD, PhD, associate chief of Ophthalmology Clinical Research at Massachusetts Eye & Ear discusses genetics of glaucoma, providing an overview of what is known about genes and gene mutations that can cause or contribute to glaucoma.

According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.

The drug is expected to be available to eye care clinicians in the US during the second half of 2023.

Researchers found through DNA sequencing and confirmed in further testing that a genetic mutation in the THBS1 gene led to the development of severe childhood glaucoma. The discovery may improve disease screening and personalize treatments.

According to investigators, retinal aging caused by stress produces symptoms similar to those resulting from natural aging.

The case series included 12 eyes of children with refractory childhood glaucoma who needed trabeculectomy or implantation of a glaucoma drainage device.

Company officials will drive global commercialization strategy for the company’s novel, non-invasive micron-accurate, OCT-guided femtosecond laser procedure for the treatment of glaucoma.

By placing the chin on the chinrest, Nidek’s NT-1p automatically detects the position of the eyes and begins measurement without pressing any buttons.

According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.

According to investigators, findings may underscore the need for sleep therapy in patients at risk for glaucoma, and frequent eye checkups for patients who are poor sleepers.

Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.

Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.

Nicox reports that daily dosing of NCX 470 0.1% met the primary efficacy objective of demonstrating non-inferiority to latanoprost 0.005%.

The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.

Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.

Complimentary registration is open for this unique meeting designed to prepare young ophthalmologists for success in early practice.

There literally are not enough hours in a day to allow physicians to comply with all the recommendations emanating from the various constituencies involved in issuing guidelines.

An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.

Lisa M. Nijm, MD, JD, shares highlights from the Real World Ophthalmology 'After Dark' networking reception held at the American Academy of Ophthalmology annual meeting. The next Real World Ophthalmology meeting on November 5—which will be virtual—will cover important clinical, business, and personal growth areas for young ophthalmologists.

According to the company, latanoprost ophthalmic solution 0.005% successfully met the primary and all secondary endpoints, and it plans to file an NDA with the FDA in Q1 2023.